Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARRIVE: Aspirin for Moderate Risk CVD Prevention
NCT00501059Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2007
- Primary completion
- Nov 2016
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 3 trial of aspirin in cardiovascular disease (CVD), sponsored by Bayer. Started Jul 2007; status: completed.
02
Drugs
aspirin
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT00501059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00501059.